Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Philippines: These 3 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Philippines: These 3 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can KYBELLA (deoxycholic acid) generic drug versions launch in Philippines?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Philippines Patent 12,013,500,364
Patent Title: SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Philippines?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Philippines Patent 12,013,502,291
Patent Title: DHEA COMPOSITIONS FOR TREATING MENOPAUSE

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Philippines?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Philippines Patent 12,015,500,727
Patent Title: PHARMACEUTICAL COMPOSITIONS

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

Philippines Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks, and Commercial Outlook

Last updated: October 11, 2026

The Philippines is a high-volume, price-sensitive pharmaceutical market where branded generics dominate private-sector dispensing and originator products retain strength in patented, specialty, hospital, and physician-driven segments. Regulatory opportunities are concentrated in generic substitution, local manufacturing, biosimilars, government procurement, e-pharmacy, and ASEAN-aligned registration. The main constraints are price controls, FDA registration delays, fragmented distribution, weak enforcement against unauthorized products, procurement concentration, and limited visibility into patent and exclusivity risks.

What is the structure of the Philippine branded and generic drug market?

The market has four main commercial segments:

Segment Typical products Main channel Competitive basis
Originator brands Patent-protected or formerly patented medicines Specialists, hospitals, private retail Clinical reputation, innovation, physician loyalty
Branded generics Off-patent active ingredients sold under proprietary names Private pharmacies, clinics, hospitals Brand recognition, sales force, price
Unbranded generics Products sold primarily by generic name Government procurement, hospitals, low-income retail Lowest price, availability, procurement compliance
Biosimilars and biologics Insulin, monoclonal antibodies, recombinant proteins Hospitals, specialty pharmacies, government programs Regulatory approval, interchangeability perception, price

Branded generics are the most commercially important competitive model in private retail. Manufacturers compete through physician promotion, pharmacy relationships, distributor coverage, stock availability, and price discounts. The Philippines therefore differs from markets where generic substitution is driven mainly by automatic pharmacy substitution.

The Department of Health, Philippine Health Insurance Corporation, private hospitals, pharmacy chains, independent drugstores, wholesalers, and public procurement agencies create separate purchasing dynamics. Private retail is fragmented, while government procurement is more concentrated and price-driven.

Which companies compete in the Philippine pharmaceutical market?

The competitive field includes multinational originators, Philippine-based manufacturers, regional generic companies, and multinational generic suppliers. Local and regional companies have strong positions in branded generics because they understand physician prescribing patterns, provincial distribution, local tender requirements, and pharmacy economics.

Important commercial participants include:

  • United Laboratories, Inc. and its consumer-health businesses;
  • Pascual Laboratories;
  • RiteMED and associated domestic manufacturing and distribution operations;
  • Lloyd Laboratories;
  • AM-Europharma;
  • Getz Pharma;
  • Kalbe Philippines;
  • multinational originator companies such as Johnson & Johnson, Pfizer, Novartis, Sanofi, AstraZeneca, Roche, Merck, and GlaxoSmithKline;
  • multinational generic and biosimilar suppliers operating through local affiliates or distributors.

Market rankings vary by data provider and by whether sales are measured at ex-manufacturer, distributor, retail, or hospital level. Public sources do not provide a single authoritative market-share database covering all channels.

How does the Philippine Generics Act affect branded and generic medicines?

Republic Act No. 6675, the Generics Act of 1988, requires the use of generic names in prescribing, labeling, advertising, procurement, and dispensing. The law does not eliminate trademarks. Companies can continue to market a generic medicine under a brand name, provided the generic name is properly displayed.

The law creates three practical effects:

  1. Physicians must identify the active ingredient by generic name.
  2. Pharmacies must make generic alternatives visible to consumers.
  3. Manufacturers can still differentiate products through trademarks, promotion, packaging, quality reputation, and availability.

The result is a market in which generic naming is mandatory but branded competition remains strong. Brand loyalty among physicians and patients can reduce the expected price erosion after patent expiry, particularly for chronic medicines.

Republic Act No. 9502, the Universally Accessible Cheaper and Quality Medicines Act of 2008, strengthened the government’s price and competition powers. It amended intellectual-property and medicines legislation to support parallel importation, competition, price regulation, and access to lower-cost medicines. [1]

What is the FDA registration process for drugs in the Philippines?

The Philippine Food and Drug Administration regulates pharmaceutical registration, licensing, manufacturing, importation, distribution, advertising, and post-market surveillance under Republic Act No. 9711. A product generally requires a Certificate of Product Registration before commercial distribution. Establishments require the applicable License to Operate. [2]

What regulatory pathway applies to a generic drug?

A conventional generic applicant normally submits evidence covering:

  • pharmaceutical equivalence;
  • quality, safety, and efficacy;
  • manufacturing and quality-control systems;
  • stability;
  • labeling and product information;
  • bioavailability or bioequivalence where required;
  • Good Manufacturing Practice compliance;
  • legal authorization and foreign manufacturing documentation where applicable.

The Philippines uses the ASEAN Common Technical Dossier structure for many pharmaceutical applications. ASEAN harmonization reduces duplication for companies with regional regulatory strategies, although national review, local administrative requirements, manufacturing inspections, and labeling controls remain relevant.

For immediate-release oral solid products, bioequivalence is often the central technical issue. Applicants must select an acceptable reference product and comply with FDA requirements for study design, analytical validation, statistical analysis, and laboratory documentation.

What is the FDA status of branded generics?

"Branded generic" is primarily a commercial description rather than a separate patent category. The product must meet the FDA requirements applicable to its formulation and legal classification. A proprietary name does not create regulatory exclusivity and does not prevent competing applicants from registering an equivalent medicine under another name.

Registration risk is highest where the applicant has:

  • weak bioequivalence data;
  • incomplete manufacturing records;
  • an unreliable foreign site;
  • inconsistent stability results;
  • labeling that does not comply with generic-name requirements;
  • unresolved ownership or authorization documents;
  • promotional claims exceeding the approved indication.

How long does drug exclusivity last in the Philippines?

A Philippine patent generally lasts 20 years from the filing date, subject to statutory requirements and payment of maintenance fees under Republic Act No. 8293, as amended. [3] There is no broad U.S.-style patent-term restoration system for pharmaceutical products.

The practical exclusivity timeline is therefore driven by:

Protection Typical legal position
Compound patent Up to 20 years from filing
Formulation patent Up to 20 years from filing, if valid and enforceable
Method-of-use patent Up to 20 years from filing, subject to claim scope
Manufacturing-process patent Up to 20 years from filing
Regulatory data exclusivity No broad, clearly defined standalone pharmaceutical period equivalent to the U.S. five-year system
Trademark Renewable indefinitely in successive periods if maintained
FDA registration Product authorization, not market exclusivity

Patent term must be calculated from the actual Philippine filing or priority position. A global launch date cannot be used to determine Philippine expiry.

Does the Philippines have an Orange Book?

No. The Philippines does not operate an Orange Book equivalent that systematically lists approved products, patents, and certified patent statements. The Philippine FDA product-registration system is separate from patent-clearance analysis.

Companies seeking Philippine launch clearance must conduct their own freedom-to-operate review using:

  • Philippine patent records;
  • WIPO Patentscope;
  • international family data;
  • published patent applications;
  • local litigation records;
  • product claims and manufacturing processes;
  • ownership and assignment records.

The absence of an Orange Book reduces transparency for generic applicants and increases the importance of local patent searches.

What patent risks affect generic entry in the Philippines?

Generic entry risk is usually highest for products with:

  • active compound patents still in force;
  • multiple formulation or delivery patents;
  • device patents covering injectors, inhalers, or autoinjectors;
  • manufacturing-process patents;
  • method-of-use claims covering the commercial indication;
  • pending continuation or divisional applications;
  • difficult-to-reproduce biologic manufacturing processes.

A generic applicant can face patent infringement exposure even where the active ingredient is off patent. Formulation, polymorph, salt, dosage, process, and use claims may extend practical barriers, although each claim must be assessed for validity, scope, and enforceability in the Philippines.

Are Paragraph IV challenges available in the Philippines?

No U.S.-style Paragraph IV certification system applies. Philippine law does not provide the same statutory ANDA certification framework or automatic 30-month stay associated with a U.S. patent challenge.

A generic applicant may instead:

  • challenge patent validity or enforceability;
  • seek a declaration of non-infringement;
  • defend an infringement action;
  • rely on a patent-expired product;
  • design around valid claims;
  • contest the scope of a method-of-use or process patent;
  • use compulsory licensing mechanisms in qualifying circumstances.

FDA registration and patent litigation are separate processes. Regulatory approval does not establish freedom to operate, and a patent dispute does not automatically create a statutory FDA stay equivalent to the U.S. model.

What is the biosimilar and biologic opportunity in the Philippines?

The Philippines has a growing opportunity for biosimilars and lower-cost biologics in oncology, diabetes, autoimmune disease, renal care, and hospital medicine. The commercial opportunity is supported by high biologic prices, public-health budget pressure, and demand for expanded access.

Biosimilar barriers include:

  • limited domestic biologics manufacturing capacity;
  • high analytical and clinical development costs;
  • cold-chain requirements;
  • physician concerns about interchangeability;
  • hospital formulary restrictions;
  • procurement qualification requirements;
  • limited local pharmacovigilance data;
  • complex biological manufacturing know-how.

A biosimilar applicant must distinguish regulatory similarity from automatic substitution. Approval does not necessarily mean that pharmacists can substitute the product without prescriber involvement. Interchangeability, naming, substitution, and procurement treatment depend on applicable FDA and health-system rules.

Patent review must cover the reference biologic, formulation, delivery device, manufacturing process, dosing regimen, and indication-specific claims. Because biologics are often protected by layered patent families, biosimilar risk is more complex than the expiry of a single compound patent.

What pricing rules affect Philippine drug manufacturers?

The government can impose maximum retail prices and maximum wholesale prices on covered medicines. Presidential Executive Order No. 821 established maximum retail price mechanisms for selected medicines, while later government measures have expanded or modified price-control and price-monitoring programs. [4]

Price controls affect:

  • originator medicines with high public-health relevance;
  • selected chronic-disease medicines;
  • essential medicines;
  • products sold through government programs;
  • medicines subject to emergency or affordability measures.

Controlled prices can improve access but reduce commercial incentives for imported originators and premium branded generics. They can also compress margins for distributors and pharmacies, especially where logistics costs are high.

Companies should model separate economics for:

  • Metro Manila private retail;
  • provincial retail;
  • hospital supply;
  • government tenders;
  • specialty products;
  • cold-chain products;
  • products subject to maximum-price regulation.

What government procurement opportunities exist?

Government procurement is a major opportunity for suppliers able to meet price, volume, quality, and delivery requirements. The Philippine Government Electronic Procurement System and public bidding processes create access to national and local government contracts. The Department of Health and other agencies procure medicines for hospitals and public-health programs.

Key opportunities include:

  • essential medicines;
  • tuberculosis and HIV treatment;
  • vaccines;
  • insulin and diabetes products;
  • oncology medicines;
  • maternal and child-health products;
  • hospital injectables;
  • biosimilars;
  • medicines supplied under PhilHealth-supported care.

Tender participation requires more than FDA registration. Suppliers must manage:

  • Philippine manufacturing or import authorization;
  • GMP documentation;
  • bid security and eligibility requirements;
  • supply guarantees;
  • delivery performance;
  • shelf-life requirements;
  • cold-chain controls;
  • local distributor capability;
  • government payment cycles.

Low-price tendering can produce volume but weak margins. A supplier that relies on government procurement should stress-test delayed awards, bid cancellations, competitor undercutting, and contract-performance penalties.

What regulatory opportunities are available for foreign pharmaceutical companies?

Foreign companies can enter through several models:

Local registration and distribution

The company appoints a Philippine importer, distributor, or authorized representative. This is the lowest-capital model but creates dependence on the local partner’s regulatory, commercial, and supply-chain performance.

Licensing and technology transfer

A foreign company licenses a brand, formulation, process, or manufacturing technology to a Philippine company. This can reduce import dependence and improve tender competitiveness. The agreement should allocate FDA obligations, pharmacovigilance, patent enforcement, technology ownership, and product liability.

Local manufacturing

Local production can improve access to government procurement, reduce import exposure, and support regional ASEAN supply. The main barriers are capital expenditure, validation, utilities, skilled personnel, quality systems, and scale economics.

Contract manufacturing

Contract manufacturing is suitable for branded generics and selected hospital products. Due diligence should cover FDA inspection history, batch-release systems, data integrity, change-control procedures, and capacity allocation.

Consumer-health and OTC expansion

OTC medicines, vitamins, supplements, and consumer-health brands benefit from pharmacy visibility and e-commerce growth. The risk is that promotional claims, influencer marketing, and online sales can trigger FDA enforcement if they exceed approved indications or use unauthorized claims.

What litigation and settlement issues affect the market?

Pharmaceutical disputes may involve:

  • patent infringement;
  • trademark infringement;
  • parallel importation;
  • counterfeit medicines;
  • unauthorized online sales;
  • regulatory enforcement;
  • product liability;
  • distributor termination;
  • unpaid government or private supply contracts.

The Philippines does not maintain a single public database equivalent to the U.S. FDA Orange Book combined with Hatch-Waxman litigation records. Litigation activity must be assessed through Philippine court records, Intellectual Property Office proceedings, FDA enforcement notices, and company disclosures.

Settlement agreements can address launch timing, licensing, supply, or patent claims. Their commercial effect depends on whether the agreement is limited to the parties, whether it grants a license, and whether the FDA product registration remains valid. Companies should not assume that a foreign patent settlement controls Philippine launch rights.

How strong is the Philippine patent estate for originator drugs?

Patent strength is generally weaker where protection depends on a single late-filed formulation or method-of-use patent and stronger where the originator has:

  • a valid compound patent;
  • multiple independent formulation claims;
  • device or delivery-system protection;
  • process patents that are difficult to design around;
  • enforceable trademarks;
  • strong manufacturing know-how;
  • regulatory and physician loyalty;
  • hospital formulary control.

The Philippines is a price-sensitive market, so commercial erosion can begin before formal patent expiry through imported alternatives, hospital tenders, and branded-generic substitution. Patent owners should separate legal exclusivity from practical market share.

How does the Philippines compare with other ASEAN markets?

The Philippines has a large English-speaking commercial base, strong private pharmacy networks, and an established branded-generic sector. Its weaknesses include regulatory congestion, uneven provincial distribution, price sensitivity, and limited transparency on patent linkage.

Factor Philippines Indonesia Vietnam Thailand
Generic-market model Strong branded generics Large domestic-generic base Strong domestic and tender competition Broad public procurement and generic use
Regulatory framework FDA plus ASEAN CTD BPOM-centered DAV-centered Thai FDA
Patent term Generally 20 years from filing Generally 20 years Generally 20 years Generally 20 years
Orange Book equivalent No No U.S.-style system No U.S.-style system No U.S.-style system
Price sensitivity High High High High
Local manufacturing role Important and expanding Very strong Strong Strong
Main access channel Private retail plus public procurement Public and private Public and private Public procurement and private

The Philippines is attractive for companies that can combine regulatory execution with local commercial coverage. It is less attractive for products requiring premium pricing without strong clinical differentiation or reimbursement support.

What are the main generic-launch scenarios?

Low-risk launch

The active ingredient and relevant formulation patents have expired, no credible process or use claims remain, and the applicant has an FDA-ready bioequivalence package.

Managed-risk launch

Compound protection has expired, but formulation, device, process, or method-of-use patents remain. The applicant launches only after a Philippine freedom-to-operate review and may use a design-around strategy.

High-risk launch

A compound or biologic patent remains active, the reference product has multiple patent families, or the applicant lacks a defensible non-infringement position. FDA approval may be commercially useful but does not eliminate infringement exposure.

Government-first launch

The applicant targets public tenders and hospital supply before broad private-retail promotion. This approach can generate volume but may create price anchoring and limited brand equity.

Key Takeaways

  • Branded generics are central to Philippine private-sector competition.
  • Generic names are mandatory, but trademarks remain commercially powerful.
  • The Philippine FDA registration system is separate from patent clearance.
  • The Philippines has no U.S.-style Orange Book or Paragraph IV procedure.
  • Patent terms generally run 20 years from filing, with no broad pharmaceutical patent-term restoration system.
  • Formulation, device, manufacturing-process, and method-of-use patents can delay generic entry after compound expiry.
  • Biosimilars have substantial access potential but face analytical, manufacturing, procurement, and substitution barriers.
  • Government tenders offer volume but create price and execution risk.
  • Price controls can compress originator, generic, and distributor margins.
  • Local regulatory and distribution partners remain important for foreign entrants.
  • The strongest market-entry strategies combine FDA readiness, Philippine patent analysis, local supply capability, and channel-specific pricing.

FAQs About the Philippine Drug Market

Does FDA approval mean a generic can launch immediately in the Philippines?

No. FDA approval authorizes the product from a regulatory perspective but does not resolve Philippine patent infringement, trademark, contractual, or distribution issues.

Can Philippine pharmacies substitute a generic without physician approval?

Generic prescribing is required, but substitution practices depend on the prescription, product classification, pharmacy rules, and applicable FDA and health-system requirements. Approval as a generic does not automatically create unrestricted substitution rights.

Are branded generics cheaper than originator medicines in the Philippines?

Usually, but the discount varies by therapeutic class, channel, brand reputation, distributor terms, and price controls. Some established branded generics maintain substantial premiums over unbranded products.

Are biosimilars automatically interchangeable with originator biologics?

No. Biosimilar approval and automatic pharmacy substitution are separate issues. Interchangeability and substitution depend on Philippine regulatory and institutional rules.

Can a foreign pharmaceutical company sell directly to Philippine consumers?

Commercial distribution generally requires the appropriate Philippine FDA authorization, licensed establishments, compliant labeling, and an approved distribution model. Cross-border online sales can create regulatory, customs, product-liability, and counterfeit risks.

References

  1. Republic of the Philippines. (2008). Republic Act No. 9502: Universally Accessible Cheaper and Quality Medicines Act of 2008. Official Gazette of the Republic of the Philippines.

  2. Republic of the Philippines. (2009). Republic Act No. 9711: Food and Drug Administration Act of 2009. Official Gazette of the Republic of the Philippines.

  3. Republic of the Philippines. (1997). Republic Act No. 8293: Intellectual Property Code of the Philippines, as amended. Intellectual Property Office of the Philippines.

  4. Office of the President of the Philippines. (2009). Executive Order No. 821: Providing for the Maximum Retail Price of Selected Drugs and Medicines. Official Gazette of the Republic of the Philippines.

  5. Republic of the Philippines. (1988). Republic Act No. 6675: Generics Act of 1988. Official Gazette of the Republic of the Philippines.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.